Avantor (Avantor) Risk Assessment

View and export this data going back to 2019. Start your Free Trial

What is Avantor Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Avantor is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Avantor's Risk Assessment

For the Specialty Chemicals subindustry, Avantor's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avantor's Risk Assessment Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Avantor's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Avantor's Risk Assessment falls into.

Avantor (NYSE:AVTR) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Avantor Risk Assessment Related Terms

Thank you for viewing the detailed overview of Avantor's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Avantor (Avantor) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Avantor Inc (NYSE:AVTR) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

AVG:Germany

Address

100 Matsonford Road, Suite 200, Building One, Radnor Corporate Center, Radnor, PA, USA, 19087

Website

https://www.avantorsciences.com

Avantor Inc is involved in providing products and services to biopharma, healthcare, education and government, and advanced technologies and applied materials industries. The company's offerings include materials and consumables, equipment and instrumentation and services and specialty procurement. Its brand profile consists of NuSil, RANKEM, POCH, BeneSphera, and Macron Fine Chemicals among others. The firm operates in three geographical segments namely Americas, Europe, and AMEA. It generates a majority of its revenue from the Americas.

Executives

Benoit Gourdier	officer: EVP, Biopharma Production	100 MATSONFORD ROAD, RADNOR PA 19087
Steven W Eck	officer: SVP & Chief Accounting Officer	C/O CSS INDUSTRIES, INC., 450 PLYMOUTH ROAD, SUITE 300, PLYMOUTH MEETING PA 19462
Frederic Vanderhaegen	officer: EVP, Europe	C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087
Brittany Hankamer	officer: EVP, Chief HR Officer	100 MATSONFORD ROAD, RADNOR PA 19087
R. Brent Jones	officer: EVP, Chief Financial Officer	C/O PALL CORPORATION, 25 HARBOR PARK DRIVE, PORT WASHINGTON NY 11050
Claudius Sokenu	officer: EVP, Chief Legal & Compliance	C/O UNISYS CORPORATION, 801 LAKEVIEW DRIVE, BLUE BELL PA 19422
Randy Lee Stone	officer: EVP, Proprietary Products	974 CENTRE ROAD, CRP 730, WILMINGTON DE 19805
Christophe Couturier	officer: See Remarks	9 FOURTH AVENUE, C/O OVASCIENCE INC., CAMBRIDGE MA 02451
Gerard Brophy	officer: EVP, Biopharma Production	C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087
Kitty Sahin	officer: EVP, Strategy&Corp Development	100 MATSONFORD ROAD, RADNOR PA 19087
Thomas A Szlosek	officer: EVP and CFO	HONEYWELL INTERNATIONAL INC., 115 TABOR ROAD, MORRIS PLAINS NJ 07950
Michael Stubblefield	director, officer: President and CEO	C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087
Rajiv Gupta	director	234 RAVENCLIFF DRIVE, ST DAVIDS PA 19087
Joseph R Massaro	director	5725 DELPHI DRIVE, TROY MI 48098
Mala Murthy	director	C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577